Rose Chang
Education
Sc.D., epidemiology, and M.S., biostatistics, Harvard T.H. Chan School of Public Health; M.S.P.H, epidemiology, Rollins School of Public Health of Emory University; B.Sc.H., life sciences, Queen’s University
Summary of Experience
Dr. Chang specializes in epidemiology and outcomes research, including the application of advanced methods to generate real-world evidence (RWE) on unmet needs, treatment patterns, and drug safety and effectiveness. She has experience working across therapeutic areas with various types of health care data, including administrative insurance claims, electronic medical records, medical chart reviews, clinical trials, patient and physician surveys, and patient registries. Dr. Chang has provided regulatory and strategic consulting on RWE generation and conducted several RWE studies to contextualize clinical trial results for regulatory new drug application (NDA) and supplemental new drug application (sNDA) submissions. Her work has been presented at scientific conferences and published in several peer-reviewed medical journals. Prior to joining Analysis Group, Dr. Chang worked as a research trainee and a teaching assistant at the Harvard T.H. Chan School of Public Health.
-
Improved Health Outcomes in Patients with Systemic Lupus Erythematosus Following Early Belimumab Initiation Without Prior Immunosuppressant Use: A Real-World Descriptive Study
Rheumatology and Therapy, 2024
2024Rubin B, Chen Y, Worley K, Rabideau B, Wu B, Chang R, DerSarkissian M
-
Impact of Therapy Management on Axitinib-Related Adverse Events in Patients with Advanced Renal Cell Carcinoma Receiving First-Line Axitinib + checkpoint Inhibitor
Clinical Genitourinary Cancer, 2023
2023Zakharia Y, Huynh L, Du S, Chang R, Pi S, Sundaresan S, Duh MS, Zanotti G, Thomaidou D
-
Time and Personnel Costs Associated with Adverse Event (AE) Management among Patients with Chronic Lymphocytic Leukemia (CLL)
Expert Review of Pharmacoeconomics & Outcomes Research, 2023
2023Patel H, Wahlstrom SK, DerSarkissian M, Kunzweiler C, Castriota F, Chang R, Gu Y, Guo H, Duh MS, Ryan KJ
-
Characteristics, Treatment Patterns, and Clinical Outcomes of Chronic Hepatitis B across 3 Continents: Retrospective Database Study
Advances in Therapy, 2023
2023Gillespie IA, Chan KA, Liu Y, Hsieh SF, Schindler C, Cheng W, Chang R, Kap E, Morais E, Duh MS, Park S, Ketz M, Jenner S, Boxall N, Kendrick S, Theodore D
-
Estimating the US pericarditis prevalence using National Health Encounter Surveillance Databases
Current Medical Research and Opinion, 2022
2022Luis SA, LeWinter MM, Magestro M, DerSarkissian M, Duh MS, Chang R, Kponee-Shovein K, Muthukumar A, Hu X, Lim-Watson MZ, Klein AL
-
Determinants of Meningococcal ACWY vaccination in adolescents in the US: completion and compliance with the CDC recommendations
Human Vaccines & Immunotherapeutics, 2020
2020 -
Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group
The Oncologist, 2020
2020Savard MF, Wells JC, Graham J, Dudani S, Steinharter JA, McGregor BA, Donskov F, Bjarnason GA, Vaishampayan UN, Hansen AR, Iafolla MAJ, Zanotti G, Huynh L, Chang R, Duh MS, Heng DYC
-
Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors
European Urology Oncology, 2019
2019Graham J, Shah AY, Wells JC, McKay RR, Vaishampayan U, Hansen A, Donskov F, Bjarnason GA, Beuselinck B, De Velasco G, Iafolla M, Duh MS, Huynh L, Chang R, Zanotti G, Ramaswamy K, Choueiri TK, Tannir NM, Heng DYC
-
August 24, 2024
-
April 4, 2024
-
December 7, 2022
-
December 10, 2021